ELX-MD-03: A Phase 2 Randomized Double-Blind Placebo-Controlled Parallel-Group Dose-Ranging Study to Evaluate the Safety and Efficacy of Eluxadoline in Pediatric Patients (Age 12 to 17 Years) with Irritable Bowel Syndrome with Diarrhea (IBS-D)
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
The purpose of this study is to look into the safety or efficacy of eluxadoline in the treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D).
Description
The primary objectives of this study are to explore the therapeutic effect of eluxadoline in treating IBS-D in pediatric patients 12-17 years of age, to evaluate the PK of eluxadoline in pediatric patients with IBS-D, and to evaluate the safety and tolerability of eluxadoline in pediatric patients with IBS-D.
Details
| Condition | Irritable Bowel Syndrome with Diarrhea |
|---|---|
| Age | 12years - 17years |
| Clinical Study Identifier | TX8950 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.